Related Experiment Video
Updated: Mar 1, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.5K
Should CYP2D6 be genotyped when treating with tamoxifen?
Marzia Del Re1, Eleonora Rofi1, Valentina Citi2
1Clinical Pharmacology & Pharmacogenetics Unit, Department of Clinical & Experimental Medicine, University of Pisa, Italy.
Pharmacogenomics
|June 9, 2017
Summary
Genotyping for the CYP2D6 enzyme is recommended for patients undergoing tamoxifen treatment for breast cancer. This ensures optimal drug metabolism and therapeutic efficacy.
Area of Science:
- Pharmacogenomics
- Oncology
- Drug Metabolism
Background:
- Tamoxifen is a crucial endocrine therapy for breast cancer.
- CYP2D6 enzyme activity significantly influences tamoxifen's metabolic activation.
- Variations in CYP2D6 genotype can lead to altered tamoxifen efficacy.
Purpose of the Study:
- To discuss the clinical relevance of CYP2D6 genotyping in tamoxifen therapy.
- To evaluate the impact of CYP2D6 genetic variations on breast cancer treatment outcomes.
- To advocate for personalized medicine approaches in oncology.
Main Methods:
- Review of existing literature on tamoxifen pharmacogenomics.
- Analysis of clinical data linking CYP2D6 genotypes to treatment response.
- Discussion of guidelines and recommendations for CYP2D6 testing.
Main Results:
- Patients with poor metabolizer CYP2D6 genotypes may experience reduced tamoxifen efficacy.
- Genotyping can identify individuals at risk of suboptimal treatment response.
- Evidence supports the routine use of CYP2D6 genotyping in clinical practice.
Conclusions:
- CYP2D6 genotyping should be considered a standard part of tamoxifen treatment for breast cancer patients.
- Personalized dosing strategies based on CYP2D6 genotype can optimize therapeutic outcomes.
- Further research is warranted to fully elucidate the role of pharmacogenomics in breast cancer management.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
51
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
51
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
65
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
01:27Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
42
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
01:29Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53